New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
08:09 EDTGNCAGenocea announces Phase 2 GEN-003 optimization trial
Genocea Biosciences announced the start of a Phase 2 dose optimization trial for GEN-003. The Phase 2 dose optimization study will enroll approximately 300 subjects from 17 institutions in the U.S. and will study six combinations of two antigen doses with each of three adjuvant doses alongside a placebo. All subjects will receive three doses of GEN-003 or placebo at 21-day intervals. The primary end point for the study is the change from baseline in viral shedding rate. The study is also designed to evaluate the impact on percentage of days with genital herpes lesions as reported by patients. Subjects receiving GEN-003 will be followed for 12 months after the last dose. Previously the company announced results from its Phase 1/2a clinical trial of GEN-003, which demonstrated, in the 30 microgram dose group, statistically significant reductions from baseline in viral shedding and genital lesion rates of up to 52% and 65% respectively, with a durability of effect to six months after dosing. The company said, "We look forward to announcing interim results from this trial in the middle of 2015.
News For GNCA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
09:21 EDTGNCAOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Constellation Brands (STZ), up 3.7%. ALSO HIGHER: Sunedison (SUNE), up 9.3% after the Wall Street Journal reported that SunEdison won't complete its $700M planned purchase of Latin American Power... Genocea Biosciences (GNCA), up 18.6% after reporting positive data from its Phase 2 trial of GEN-003... Lion Biotechnologies (LBIO), up 13.3% after obtaining an exclusive, worldwide license from the National Institutes of Health to develop and commercialize tumor-infiltrating lymphocytes therapy in four additional tumor indications... Juniper Networks (JNPR), up 3.3% after Light Reading reported that several Silicon Valley sources confirmed the speculation that Juniper Networks hired Goldman Sachs (GS) to explore interest in taking the company private. DOWN AFTER EARNINGS: Monsanto (MON), down 5%... Yum! Brands (YUM), down 15.3%. ALSO LOWER: Axion Power (AXPW), down 40.5% after reporting that it is no longer feasible or possible to complete the LCB International transaction... Advaxis (ADXS), down 20.4% following its report of a clinical hold of axalimogene filolisbac... Neonode (NEON), down 14.5% after 3.2M share Secondary priced at $1.90 and providing third quarter revenue... Adobe (ADBE), down 3.2% after providing growth target guidance for fiscal 2015 through fiscal 2018 and fiscal 2016 guidance... J.C. Penney (JCP), down 2% after being initiated with a sell at Citi.
07:34 EDTGNCAGenocea to host conference call
Subscribe for More Information
07:04 EDTGNCAGenocea says Phase 2 trial of GEN-003 data 'positive'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use